Early growth response- (Egr-) 1 is an upstream master switch in controlling inflammatory responses following
myocardial ischemia-reperfusion (I/R). Activation of extracellular signal-regulated
protein kinase-1 and kinase-2 (ERK1/2) signaling is known to upregulate Egr-1. ERK1/2 pathway has been previously shown to mediate the therapeutic action of electroacupucture (EA). Thus, we hypothesized that EA would reduce myocardial I/R injury and inflammatory responses through inhibiting Egr-1 expression via the ERK1/2 pathway. Mice were pretreated with EA,
U0126, or combination of EA and
U0126 and then underwent 1 h
myocardial ischemia and 3 h reperfusion. We investigated that EA significantly attenuated the I/R-induced upregulation of both Egr-1 and phosporylated-ERK1/2 (p-ERK1/2), decreased myocardial inflammatory
cytokines including
tumor necrosis factor- α (TNF- α ) and
interleukin-1 β (IL-1 β ), and reduced the
infarct size and the release of cardiac
troponin I (cTnI).
U0126 treatment also exhibited the same effect as EA on Egr-1 level and subsequent cardioprotective effects. There was no additive effect of cotreatment with EA and
U0126 on the expression of Egr-1 and its downstream target genes (TNF- α , IL-1 β ) or serum cTnI level. Collectively, these observations suggested that EA attenuates myocardial I/R injury, possibly through inhibiting the ERK1/2-Egr-1 signaling pathway and reducing the release of proinflammatory
cytokines.